Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Evaluation of Pharmacodynamic Responses to Cancer Therapeutic Agents Using DNA Damage Markers.

Wilsker DF, Barrett AM, Dull AB, Lawrence SM, Hollingshead MG, Chen A, Kummar S, Parchment RE, Doroshow JH, Kinders RJ.

Clin Cancer Res. 2019 May 15;25(10):3084-3095. doi: 10.1158/1078-0432.CCR-18-2523. Epub 2019 Feb 21.

PMID:
30792217
2.

Novel antibody reagents for characterization of drug- and tumor microenvironment-induced changes in epithelial-mesenchymal transition and cancer stem cells.

Navas T, Pfister TD, Colantonio S, Aziz A, Dieckman L, Saul RG, Kaczmarczyk J, Borgel S, Alcoser SY, Hollingshead MG, Lee YH, Bottaro DP, Hiltke T, Whiteley G, Takebe N, Kinders RJ, Parchment RE, Tomaszewski JE, Doroshow JH.

PLoS One. 2018 Jun 21;13(6):e0199361. doi: 10.1371/journal.pone.0199361. eCollection 2018.

3.

Molecular Pharmacodynamics-Guided Scheduling of Biologically Effective Doses: A Drug Development Paradigm Applied to MET Tyrosine Kinase Inhibitors.

Srivastava AK, Hollingshead MG, Govindharajulu JP, Covey JM, Liston D, Simpson MA, Peggins JO, Bottaro DP, Wright JJ, Kinders RJ, Doroshow JH, Parchment RE.

Mol Cancer Ther. 2018 Mar;17(3):698-709. doi: 10.1158/1535-7163.MCT-17-0552. Epub 2018 Feb 14.

4.

Effective implementation of novel MET pharmacodynamic assays in translational studies.

Srivastava AK, Navas T, Herrick WG, Hollingshead MG, Bottaro DP, Doroshow JH, Parchment RE.

Ann Transl Med. 2017 Jan;5(1):3. doi: 10.21037/atm.2016.12.78. Review.

5.

Pharmacodynamic Response of the MET/HGF Receptor to Small-Molecule Tyrosine Kinase Inhibitors Examined with Validated, Fit-for-Clinic Immunoassays.

Srivastava AK, Hollingshead MG, Weiner J, Navas T, Evrard YA, Khin SA, Ji JJ, Zhang Y, Borgel S, Pfister TD, Kinders RJ, Bottaro DP, Linehan WM, Tomaszewski JE, Doroshow JH, Parchment RE.

Clin Cancer Res. 2016 Jul 15;22(14):3683-94. doi: 10.1158/1078-0432.CCR-15-2323. Epub 2016 Mar 21.

6.

Effect of a Smac Mimetic (TL32711, Birinapant) on the Apoptotic Program and Apoptosis Biomarkers Examined with Validated Multiplex Immunoassays Fit for Clinical Use.

Srivastava AK, Jaganathan S, Stephen L, Hollingshead MG, Layhee A, Damour E, Govindharajulu JP, Donohue J, Esposito D, Mapes JP, Kinders RJ, Takebe N, Tomaszewski JE, Kummar S, Doroshow JH, Parchment RE.

Clin Cancer Res. 2016 Feb 15;22(4):1000-10. doi: 10.1158/1078-0432.CCR-14-3156. Epub 2015 Oct 7.

7.

Gene expression profiling of 49 human tumor xenografts from in vitro culture through multiple in vivo passages--strategies for data mining in support of therapeutic studies.

Hollingshead MG, Stockwin LH, Alcoser SY, Newton DL, Orsburn BC, Bonomi CA, Borgel SD, Divelbiss R, Dougherty KM, Hager EJ, Holbeck SL, Kaur G, Kimmel DJ, Kunkel MW, Millione A, Mullendore ME, Stotler H, Collins J.

BMC Genomics. 2014 May 22;15:393. doi: 10.1186/1471-2164-15-393.

8.

Oxyphenisatin acetate (NSC 59687) triggers a cell starvation response leading to autophagy, mitochondrial dysfunction, and autocrine TNFα-mediated apoptosis.

Morrison BL, Mullendore ME, Stockwin LH, Borgel S, Hollingshead MG, Newton DL.

Cancer Med. 2013 Oct;2(5):687-700. doi: 10.1002/cam4.107. Epub 2013 Jul 23.

9.

A small molecule (pluripotin) as a tool for studying cancer stem cell biology: proof of concept.

Mertins SD, Scudiero DA, Hollingshead MG, Divelbiss RD Jr, Alley MC, Monks A, Covell DG, Hite KM, Salomon DS, Niederhuber JE.

PLoS One. 2013;8(2):e57099. doi: 10.1371/journal.pone.0057099. Epub 2013 Feb 21.

10.

Global metabolomics reveals urinary biomarkers of breast cancer in a mcf-7 xenograft mouse model.

Johnson CH, Manna SK, Krausz KW, Bonzo JA, Divelbiss RD, Hollingshead MG, Gonzalez FJ.

Metabolites. 2013 Aug 7;3(3):658-72. doi: 10.3390/metabo3030658.

11.

Identification of CBX3 and ABCA5 as putative biomarkers for tumor stem cells in osteosarcoma.

Saini V, Hose CD, Monks A, Nagashima K, Han B, Newton DL, Millione A, Shah J, Hollingshead MG, Hite KM, Burkett MW, Delosh RM, Silvers TE, Scudiero DA, Shoemaker RH.

PLoS One. 2012;7(8):e41401. doi: 10.1371/journal.pone.0041401. Epub 2012 Aug 3. Erratum in: PLoS One. 2012;7(11). doi:10.1371/annotation/8c74aaee-897d-4682-b62d-d95a3506c210.

12.

Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer.

Bennett CN, Tomlinson CC, Michalowski AM, Chu IM, Luger D, Mittereder LR, Aprelikova O, Shou J, Piwinica-Worms H, Caplen NJ, Hollingshead MG, Green JE.

Breast Cancer Res. 2012 Jul 19;14(4):R109. doi: 10.1186/bcr3230.

13.

Real-time PCR-based assay to quantify the relative amount of human and mouse tissue present in tumor xenografts.

Alcoser SY, Kimmel DJ, Borgel SD, Carter JP, Dougherty KM, Hollingshead MG.

BMC Biotechnol. 2011 Dec 16;11:124. doi: 10.1186/1472-6750-11-124.

14.

ASPS-1, a novel cell line manifesting key features of alveolar soft part sarcoma.

Kenney S, Vistica DT, Stockwin LH, Burkett S, Hollingshead MG, Borgel SD, Butcher DO, Schrump DS, Shoemaker RH.

J Pediatr Hematol Oncol. 2011 Jul;33(5):360-8. doi: 10.1097/MPH.0b013e3182002f9f.

PMID:
21552147
15.

A copper chelate of thiosemicarbazone NSC 689534 induces oxidative/ER stress and inhibits tumor growth in vitro and in vivo.

Hancock CN, Stockwin LH, Han B, Divelbiss RD, Jun JH, Malhotra SV, Hollingshead MG, Newton DL.

Free Radic Biol Med. 2011 Jan 1;50(1):110-21. doi: 10.1016/j.freeradbiomed.2010.10.696. Epub 2010 Nov 4.

16.

Sodium dichloroacetate selectively targets cells with defects in the mitochondrial ETC.

Stockwin LH, Yu SX, Borgel S, Hancock C, Wolfe TL, Phillips LR, Hollingshead MG, Newton DL.

Int J Cancer. 2010 Dec 1;127(11):2510-9. doi: 10.1002/ijc.25499.

17.

Proteomic analysis of nuclei isolated from cancer cell lines treated with indenoisoquinoline NSC 724998, a novel topoisomerase I inhibitor.

Han B, Stockwin LH, Hancock C, Yu SX, Hollingshead MG, Newton DL.

J Proteome Res. 2010 Aug 6;9(8):4016-27. doi: 10.1021/pr100194d. Erratum in: J Proteome Res. 2011 Apr 1;10(4):2128.

18.

Artemisinin dimer anticancer activity correlates with heme-catalyzed reactive oxygen species generation and endoplasmic reticulum stress induction.

Stockwin LH, Han B, Yu SX, Hollingshead MG, ElSohly MA, Gul W, Slade D, Galal AM, Newton DL, Bumke MA.

Int J Cancer. 2009 Sep 15;125(6):1266-75. doi: 10.1002/ijc.24496. Erratum in: Int J Cancer. 2010 Dec;127(11):E1. Bumke, Maja A [added].

19.

ARC (NSC 188491) has identical activity to Sangivamycin (NSC 65346) including inhibition of both P-TEFb and PKC.

Stockwin LH, Yu SX, Stotler H, Hollingshead MG, Newton DL.

BMC Cancer. 2009 Feb 20;9:63. doi: 10.1186/1471-2407-9-63.

20.

Synthesis and evaluation of dihydroartemisinin and dihydroartemisitene acetal dimers showing anticancer and antiprotozoal activity.

Galal AM, Gul W, Slade D, Ross SA, Feng S, Hollingshead MG, Alley MC, Kaur G, ElSohly MA.

Bioorg Med Chem. 2009 Jan 15;17(2):741-51. doi: 10.1016/j.bmc.2008.11.050. Epub 2008 Nov 25.

PMID:
19084416
21.

Antitumor efficacy testing in rodents.

Hollingshead MG.

J Natl Cancer Inst. 2008 Nov 5;100(21):1500-10. doi: 10.1093/jnci/djn351. Epub 2008 Oct 28.

22.

Molecular analysis reveals heterogeneity of mouse mammary tumors conditionally mutant for Brca1.

Wright MH, Robles AI, Herschkowitz JI, Hollingshead MG, Anver MR, Perou CM, Varticovski L.

Mol Cancer. 2008 Apr 7;7:29. doi: 10.1186/1476-4598-7-29.

23.

Advantage of combining NLCQ-1 (NSC 709257) with radiation in treatment of human head and neck xenografts.

Papadopoulou MV, Bloomer WD, Taylor AP, Hernandez M, Blumenthal RD, Hollingshead MG.

Radiat Res. 2007 Jul;168(1):65-71.

PMID:
17722994
24.

Proteomic analysis identifies oxidative stress induction by adaphostin.

Stockwin LH, Bumke MA, Yu SX, Webb SP, Collins JR, Hollingshead MG, Newton DL.

Clin Cancer Res. 2007 Jun 15;13(12):3667-81.

25.

Accelerated preclinical testing using transplanted tumors from genetically engineered mouse breast cancer models.

Varticovski L, Hollingshead MG, Robles AI, Wu X, Cherry J, Munroe DJ, Lukes L, Anver MR, Carter JP, Borgel SD, Stotler H, Bonomi CA, Nunez NP, Hursting SD, Qiao W, Deng CX, Green JE, Hunter KW, Merlino G, Steeg PS, Wakefield LM, Barrett JC.

Clin Cancer Res. 2007 Apr 1;13(7):2168-77.

26.

Inhibition of Akt by the alkylphospholipid perifosine does not enhance the radiosensitivity of human glioma cells.

de la Peña L, Burgan WE, Carter DJ, Hollingshead MG, Satyamitra M, Camphausen K, Tofilon PJ.

Mol Cancer Ther. 2006 Jun;5(6):1504-10.

27.

In vitro and in vivo radiosensitization induced by the ribonucleotide reductase inhibitor Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone).

Barker CA, Burgan WE, Carter DJ, Cerna D, Gius D, Hollingshead MG, Camphausen K, Tofilon PJ.

Clin Cancer Res. 2006 May 1;12(9):2912-8.

28.

NLCQ-1 (NSC 709257) in combination with radiation against human glioma U251 xenografts.

Papadopoulou MV, Bloomer WD, Hollingshead MG.

Anticancer Res. 2005 May-Jun;25(3B):1865-9.

29.

A new synthetic agent with potent but selective cytotoxic activity against cancer.

Cholody WM, Kosakowska-Cholody T, Hollingshead MG, Hariprakasha HK, Michejda CJ.

J Med Chem. 2005 Jun 30;48(13):4474-81.

PMID:
15974599
30.

Enhancement of in vitro and in vivo tumor cell radiosensitivity by the DNA methylation inhibitor zebularine.

Dote H, Cerna D, Burgan WE, Carter DJ, Cerra MA, Hollingshead MG, Camphausen K, Tofilon PJ.

Clin Cancer Res. 2005 Jun 15;11(12):4571-9.

31.

Synthesis, structure-activity relationship, and p210(bcr-abl) protein tyrosine kinase activity of novel AG 957 analogs.

Kaur G, Narayanan VL, Risbood PA, Hollingshead MG, Stinson SF, Varma RK, Sausville EA.

Bioorg Med Chem. 2005 Mar 1;13(5):1749-61.

PMID:
15698792
32.

Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin.

Bull EE, Dote H, Brady KJ, Burgan WE, Carter DJ, Cerra MA, Oswald KA, Hollingshead MG, Camphausen K, Tofilon PJ.

Clin Cancer Res. 2004 Dec 1;10(23):8077-84.

33.

SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 2: efficacy evaluations.

Alley MC, Hollingshead MG, Pacula-Cox CM, Waud WR, Hartley JA, Howard PW, Gregson SJ, Thurston DE, Sausville EA.

Cancer Res. 2004 Sep 15;64(18):6700-6.

34.

SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity.

Hartley JA, Spanswick VJ, Brooks N, Clingen PH, McHugh PJ, Hochhauser D, Pedley RB, Kelland LR, Alley MC, Schultz R, Hollingshead MG, Schweikart KM, Tomaszewski JE, Sausville EA, Gregson SJ, Howard PW, Thurston DE.

Cancer Res. 2004 Sep 15;64(18):6693-9.

35.

Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and anti-angiogenesis agents.

Adams BK, Ferstl EM, Davis MC, Herold M, Kurtkaya S, Camalier RF, Hollingshead MG, Kaur G, Sausville EA, Rickles FR, Snyder JP, Liotta DC, Shoji M.

Bioorg Med Chem. 2004 Jul 15;12(14):3871-83.

PMID:
15210154
36.

A potential role for imaging technology in anticancer efficacy evaluations.

Hollingshead MG, Bonomi CA, Borgel SD, Carter JP, Shoemaker R, Melillo G, Sausville EA.

Eur J Cancer. 2004 Apr;40(6):890-8.

PMID:
15120044
37.

"Vasocrine" formation of tumor cell-lined vascular spaces: implications for rational design of antiangiogenic therapies.

Rybak SM, Sanovich E, Hollingshead MG, Borgel SD, Newton DL, Melillo G, Kong D, Kaur G, Sausville EA.

Cancer Res. 2003 Jun 1;63(11):2812-9.

38.

Testing of new agents in childhood cancer preclinical models: meeting summary.

Houghton PJ, Adamson PC, Blaney S, Fine HA, Gorlick R, Haber M, Helman L, Hirschfeld S, Hollingshead MG, Israel MA, Lock RB, Maris JM, Merlino G, Patterson W, Reynolds CP, Shannon K, Yu A, Yu J, Smith MA.

Clin Cancer Res. 2002 Dec;8(12):3646-57.

39.

Therapeutic advantage from combining paclitaxel with the hypoxia-selective cytotoxin NLCQ-1 in murine tumor- or human xenograft-bearing mice.

Papadopoulou MV, Ji M, Ji X, Bloomer WD, Hollingshead MG.

Cancer Chemother Pharmacol. 2002 Dec;50(6):501-8. Epub 2002 Sep 26.

PMID:
12451478
40.

Enhancement of the antitumor effect of cyclophosphamide with the hypoxia-selective cytotoxin NLCQ-1 against murine tumors and human xenografts.

Papadopoulou MV, Ji M, Bloomer WD, Hollingshead MG.

J Exp Ther Oncol. 2002 Sep-Oct;2(5):298-305.

PMID:
12416033
41.

Pervilleines B and C, new tropane alkaloid aromatic esters that reverse the multidrug-resistance in the hollow fiber assay.

Mi Q, Cui B, Silva GL, Lantvit D, Lim E, Chai H, Hollingshead MG, Mayo JG, Kinghorn AD, Pezzuto JM.

Cancer Lett. 2002 Oct 8;184(1):13-20.

PMID:
12104043
42.

Evaluation of the potential cancer chemotherapeutic efficacy of natural product isolates employing in vivo hollow fiber tests.

Mi Q, Lantvit D, Reyes-Lim E, Chai H, Zhao W, Lee IS, Peraza-Sánchez S, Ngassapa O, Kardono LB, Riswan S, Hollingshead MG, Mayo JG, Farnsworth NR, Cordell GA, Kinghorn AD, Pezzuto JM.

J Nat Prod. 2002 Jun;65(6):842-50.

PMID:
12088425
43.

Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol.

Lam LT, Pickeral OK, Peng AC, Rosenwald A, Hurt EM, Giltnane JM, Averett LM, Zhao H, Davis RE, Sathyamoorthy M, Wahl LM, Harris ED, Mikovits JA, Monks AP, Hollingshead MG, Sausville EA, Staudt LM.

Genome Biol. 2001;2(10):RESEARCH0041. Epub 2001 Sep 13.

44.

Pervilleine A, a novel tropane alkaloid that reverses the multidrug-resistance phenotype.

Mi Q, Cui B, Silva GL, Lantvit D, Lim E, Chai H, You M, Hollingshead MG, Mayo JG, Kinghorn AD, Pezzuto JM.

Cancer Res. 2001 May 15;61(10):4030-7.

45.

The hollow fiber assay: continued characterization with novel approaches.

Hall LA, Krauthauser CM, Wexler RS, Hollingshead MG, Slee AM, Kerr JS.

Anticancer Res. 2000 Mar-Apr;20(2A):903-11.

PMID:
10810375
46.

Murine pharmacokinetics of 6-aminonicotinamide (NSC 21206), a novel biochemical modulating agent.

Walker DL, Reid JM, Svingen PA, Rios R, Covey JM, Alley MC, Hollingshead MG, Budihardjo II, Eckdahl S, Boerner SA, Kaufmann SH, Ames MM.

Biochem Pharmacol. 1999 Sep 15;58(6):1057-66.

PMID:
10509758
47.

Alertenone, a dimer of suberosenone from Alertigorgia sp.

Bokesch HR, Blunt JW, Westergaard CK, Cardellina JH 2nd, Johnson TR, Michael JA, McKee TC, Hollingshead MG, Boyd MR.

J Nat Prod. 1999 Apr;62(4):633-5.

PMID:
10217729
48.

In vivo anti-HIV activity of (+)-calanolide A in the hollow fiber mouse model.

Xu ZQ, Hollingshead MG, Borgel S, Elder C, Khilevich A, Flavin MT.

Bioorg Med Chem Lett. 1999 Jan 18;9(2):133-8.

PMID:
10021914
49.

Synthesis and antiviral evaluation of analogs of adenosine-N1-oxide and 1-(Benzyloxy)adenosine.

Kwong CD, Krauth CA, Shortnacy-Fowler AT, Arnett G, Hollingshead MG, Shannon WM, Montgomery JA, Secrist JA 3rd.

Nucleosides Nucleotides. 1998 Aug;17(8):1409-43.

PMID:
9672703
50.

Inhibition of in vitro and in vivo HIV replication by a distamycin analogue that interferes with chemokine receptor function: a candidate for chemotherapeutic and microbicidal application.

Howard OM, Oppenheim JJ, Hollingshead MG, Covey JM, Bigelow J, McCormack JJ, Buckheit RW Jr, Clanton DJ, Turpin JA, Rice WG.

J Med Chem. 1998 Jun 18;41(13):2184-93.

PMID:
9632350

Supplemental Content

Loading ...
Support Center